Physician profile
Roxana Sulica
NPI 1659304509
$211,498.83
in general payments reported to CMS, 2019-2025
12 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $12K · 2021: $11K · 2022: $25K · 2023: $41K · 2024: $45K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $81K · Travel and Lodging: $7,523 · Food and Beverage: $4,509 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,388 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $80,666.50 |
| Travel and Lodging | $7,523.20 |
| Food and Beverage | $4,508.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,387.50 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $82,226.78 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $60,750.13 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $36,004.45 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $27,035.92 | 2022-2025 | Winrevair |
| Chiesi USA, INC. | $4,703.90 | 2025 | |
| Insmed, INC. | $322.06 | 2019-2021 | |
| Sandoz INC. | $187.79 | 2023-2025 | Treprostinil |
| Liquidia Technologies, INC. | $165.58 | 2025 | Yutrepia |
| Gilead Sciences, INC. | $102.22 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Sulica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.